Phaseline

Targets › BCR

BCR (Breakpoint cluster region protein): drug programs, companies and trials

22 programs from 19 companies in 95 trials: 53 Phase 2, 26 Phase 1, 14 Phase 3, 2 Phase 4; Oncology, Other, Neurology; next expected readout Dec 2026.

Protein with a unique structure having two opposing regulatory activities toward small GTP-binding proteins. The C-terminus is a GTPase-activating protein (GAP) domain which stimulates GTP hydrolysis by RAC1, RAC2 and CDC42. (UniProt, P11274)

Open in Phaseline: the race on BCR, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
NovartisAsciminib
Tyrosine-protein kinase ABL inhibitor; Bcr/Abl fusion protein inhibitor
ABL1, BCRPhase 4Chronic Myelogenous Leukemia; Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive; Philadelphia Chromosome-Positive Chronic Myeloid Leukemia; Chronic Myelogenous Leukemia - Chronic Phase …Sep 2027
National Cancer Institute (NCI)Dasatinib
Bcr/Abl fusion protein inhibitor
ABL1, BCRPhase 3B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1; Acute Lymphoblastic Leukemia; Chronic Myeloid Leukemia, BCR-ABL1 Positive; B Acute Lymphoblastic Leukemia …Jan 2027
Ascentage Pharma GroupOlverembatinib
Bcr/Abl fusion protein inhibitor
ABL1, BCRPhase 3GIST; Chronic Myeloid Leukemia; Ph+ ALL; Pharmacokinetic …Mar 2027
Il-Yang Pharm.Radotinib
Bcr/Abl fusion protein inhibitor
ABL1, BCRPhase 3Chronic Myeloid Leukemia, Chronic Phase; Parkinson DiseaseApr 2027
TakedaPonatinib
Bcr/Abl fusion protein inhibitor
ABL1, BCRPhase 3Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL); Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive); B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative; Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive …Jul 2027
National Cancer Institute (NCI)Imatinib Mesylate
Tyrosine-protein kinase ABL inhibitor; Platelet-derived growth factor receptor beta inhibitor; Stem cell growth factor receptor inhibitor
ABL1, PDGFRB, KIT, BCRPhase 2Chronic Myeloid Leukemia, BCR-ABL1 Positive; B Acute Lymphoblastic Leukemia; Inherited Bone Marrow Failure SyndromeMar 2027
National Cancer Institute (NCI)Nilotinib
Tyrosine-protein kinase ABL inhibitor; Bcr/Abl fusion protein inhibitor
ABL1, BCRPhase 2Neoplasms; Metastatic Malignant Solid NeoplasmApr 2027
The Netherlands Cancer InstituteNilotinib
Tyrosine-protein kinase ABL inhibitor; Bcr/Abl fusion protein inhibitor
ABL1, BCRPhase 2CancerSep 2027
European LeukemiaNetnilotinib
Tyrosine-protein kinase ABL inhibitor; Bcr/Abl fusion protein inhibitor
ABL1, BCRPhase 2Chronic Myeloid LeukemiaSep 2027
M.D. Anderson Cancer CenterDasatinib
Bcr/Abl fusion protein inhibitor
ABL1, BCRPhase 2Chronic Phase Chronic Myelogenous Leukemia; Chronic Myeloid Leukemia; Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Advanced Malignant Solid NeoplasmOct 2027
Centre Leon BerardNilotinib
Tyrosine-protein kinase ABL inhibitor; Bcr/Abl fusion protein inhibitor
ABL1, BCRPhase 2Malignant Solid NeoplasmsJan 2028
ECOG-ACRIN Cancer Research GroupNilotinib
Tyrosine-protein kinase ABL inhibitor; Bcr/Abl fusion protein inhibitor
ABL1, BCRPhase 2Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveAug 2028
Baylor College of MedicineBosutinib
Tyrosine-protein kinase ABL inhibitor; Tyrosine-protein kinase SRC inhibitor; Tyrosine-protein kinase HCK inhibitor
ABL1, SRC, HCK, LYN, BCRPhase 2Chronic Myeloid LeukemiaNov 2028
Baylor College of MedicineNilotinib
Tyrosine-protein kinase ABL inhibitor; Bcr/Abl fusion protein inhibitor
ABL1, BCRPhase 2Chronic Myeloid LeukemiaNov 2028
Masaryk UniversityNilotinib
Tyrosine-protein kinase ABL inhibitor; Bcr/Abl fusion protein inhibitor
ABL1, BCRPhase 2Chronic Myeloid Leukemia, Chronic Phase–
OtsukaPonatinib
Bcr/Abl fusion protein inhibitor
ABL1, BCRPhase 2Chronic Myeloid Leukemia–
Taiho PharmaceuticalImatinib
Tyrosine-protein kinase ABL inhibitor; Platelet-derived growth factor receptor beta inhibitor; Stem cell growth factor receptor inhibitor
ABL1, PDGFRB, KIT, BCRPhase 1Gastrointestinal Stromal Tumors; Hematological Neoplasms; Tyrosine Kinase Inhibitors; Leukemia, Acute Lymphoblastic …Dec 2026
Enliven TherapeuticsELVN-001
Third-generation BCR-ABL tyrosine kinase inhibitor effective against T315I mutation
BCR, ABL1Phase 1Chronic Myeloid Leukemia; CML (Chronic Myelogenous Leukemia)Dec 2027
Incyte Biosciences International SàrlPonatinib
Bcr/Abl fusion protein inhibitor
ABL1, BCRPhase 1Acute Myeloid LeukemiaFeb 2028
Rina PlattnerNilotinib
Tyrosine-protein kinase ABL inhibitor; Bcr/Abl fusion protein inhibitor
ABL1, BCRPhase 1Metastatic MelanomaJul 2028
Children's Oncology GroupBosutinib
Tyrosine-protein kinase ABL inhibitor; Tyrosine-protein kinase SRC inhibitor; Tyrosine-protein kinase HCK inhibitor
ABL1, SRC, HCK, LYN, BCRPhase 1Philadelphia Chromosome Positive CMLJul 2028
Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)MK-4208 (TERN-701)
ABL kinase inhibitor
BCR, ABL1Phase 1Leukemia, Myelogenous, Chronic, BCR-ABL PositiveNov 2029

Conditions

Chronic Myeloid Leukemia (10) Chronic Myeloid Leukemia, Chronic Phase (6) Acute Lymphoblastic Leukemia (5) Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive (3) B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 (3) Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive (3) Gastrointestinal Stromal Tumors (3) Philadelphia Chromosome Positive CML (2) Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (2) Chronic Myelogenous Leukemia (2) Chronic Myeloid Leukemia (CML) (2) Chronic Phase Chronic Myelogenous Leukemia (2)

Modalities

small molecule (11), mixed (8), other (3)

Companies

National Cancer Institute (NCI) (3) Baylor College of Medicine (2) Ascentage Pharma Group (1) Il-Yang Pharm. (1) Takeda (1) Incyte Biosciences International Sàrl (1) Enliven Therapeutics (1) Novartis (1) M.D. Anderson Cancer Center (1) Taiho Pharmaceutical (1) Masaryk University (1) ECOG-ACRIN Cancer Research Group (1) Rina Plattner (1) European LeukemiaNet (1) The Netherlands Cancer Institute (1) Children's Oncology Group (1) Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (1) Centre Leon Berard (1) Otsuka (1)

Related targets

ABL1 (22) SRC (2) HCK (2) LYN (2) PDGFRB (2) KIT (2)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.